[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343106-105":59,"doc-detail-343106-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comparison-of-rivaroxaban-and-low-molecular-weight-heparin-in-the-treatment-of-cancer-associated-venous-thromboembolism-a-swedish-national-population-based-register-study","Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism - a Swedish national population-based register study","","Cancer-associated venous thromboembolism (CAT) treated with anticoagulation reduces recurrent venous thromboembolism (rVTE) but raises bleeding risk. This study compares rivaroxaban versus low molecular weight heparin (LMWH) in patients with CAT for incidence of rVTE, major bleeding, and all-cause mortality. Using Swedish national registers from 2013–2019, it estimates incidence rates per 1000 person-years and hazard ratios via propensity score overlap-weighted methods.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-rivaroxaban-and-low-molecular-weight-heparin-in-the-treatment-of-cancer-associated-venous-thromboembolism-a-swedish-national-population-based-register-study/343106/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-rivaroxaban-and-low-molecular-weight-heparin-in-the-treatment-of-cancer-associated-venous-thromboembolism-a-swedish-national-population-based-register-study/343106.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical outcomes were compared between rivaroxaban and LMWH in cancer-associated CAT?","Question",{"text":112,"@type":113},"The study compared incidence of recurrent VTE (rVTE), major bleeding, and all-cause mortality for patients with CAT treated with rivaroxaban versus LMWH.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients with cancer-associated venous thromboembolism identified and followed?",{"text":117,"@type":113},"Patients with CAT were identified as venous thromboembolism occurring within 6 months of cancer diagnosis, using Swedish national registers from 2013–2019, then followed from the index CAT date to outcome, death, emigration, or end of study.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings for recurrent VTE, major bleeding, and mortality?",{"text":121,"@type":113},"Rivaroxaban showed similar performance to LMWH for rVTE and major bleeding, while an all-cause mortality benefit was observed for rivaroxaban, potentially related to residual confounding.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343106,1790165358,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study  \nMarie Linder1 · Anders Ekbom1 · Gunnar Brobert9 · Kai Vogtländer2 · Yanina Balabanova2 · Cecilia Becattini3 · Marc Carrier4 · Alexander T. Cohen5 · Craig I. Coleman6 · Alok A. Khorana7 · Agnes Y. Y. Lee8 · George Psaroudakis2 · Khaled Abdelgawwad2 · Marcela Rivera9,10 · Bernhard Schaefer2 · Diego Hernan Giunta1  \nAccepted: 26 April 2024 / Published online: 12 May 2024 © The Author(s) 2024  \nAbstract  \nBackground Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk.  \nObjectives To compare incidence of rVTE, major bleeding, and all-cause mortality for rivaroxaban versus low molecular weight heparin (LMWH) in patients with CAT.  \nMethods We developed a cohort study using Swedish national registers 2013–2019. Patients with CAT (venous thromboembolism within 6 months of cancer diagnosis) were included. Those with other indications or with high bleeding risk cancers were excluded (according to guidelines). Follow-up was from index-CAT until outcome, death, emigration, or end of study. Incidence rates (IR) per 1000 person-years with 95% confidence interval (CI) and propensity score overlap-weighted hazard ratios (HRs) for rivaroxaban versus LMWH were estimated.  \nResults We included 283 patients on rivaroxaban and 5181 on LMWH. The IR for rVTE was 68.7 (95% CI 40.0–109.9) for rivaroxaban, compared with 91.6 (95% CI 81.9–102.0) for LMWH, with adjusted HR 0.77 (95% CI 0.43–1.35) . The IR for major bleeding was 23.5 (95% CI 8.6–51.1) for rivaroxaban versus 49.2 (95% CI 42.3–56.9) for LMWH, with adjusted HR 0.62 (95% CI 0.26–1.49) . The IR for all-cause mortality was 146.8 (95% CI 103.9–201.5) for rivaroxaban and 565.6 (95% CI 541.8–590.2) for LMWH with adjusted HR 0.48 (95% CI 0.34–0.67) .  \nConclusions Rivaroxaban performed similarly to LMWH for patients with CAT for rVTE and major bleeding. An all-cause mortality benefit was observed for rivaroxaban which potentially may be attributed to residual confounding.  \nTrial registration number NCT05150938 (Registered 9 December 2021) .  \nHighlights  \n● Treating cancer-associated venous thromboembolism with anticoagulation prevents recurrent VTE, but may increase the risk of bleeding. DOACs have easier administration and proven higher treatment adherence compared to LMWH.  \n● Excluding cancer with high risk of bleeding, rivaroxaban performed similarly to LMWH for patients with cancer and VTE for recurrent VTE and major bleeding.  \n● An all-cause mortality benefit was observed for rivaroxaban compared to LMWH which potentially may be attributed to residual confounding.  \nKeywords Cancer-associated thrombosis · Recurrent venous thromboembolism · Major bleeding · Rivaroxaban · Low molecular weight heparin  \nExtended author information available on the last page of the article  \nIntroduction  \nCancer-associated thrombosis (CAT) is a serious complication and a leading cause of death second to cancer progression among patients with cancer [1–3] . Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE) . Whether or not the long-term mortality is increased in individuals surviving the initial VTE episode is less clear [4] . Risk of VTE is 4-to 7-fold higher in patients with cancer compared with the general population [5], with incidence rates (IRs) for all cancer types ranging from 2 to 12 cases per 100 person-years [6] . The risk of recurrent VTE (rVTE) events is also increased in individuals with anticoagulants and cancer-specific treatments [6] .  \nRecommended treatments for CAT have changed recently, now including direct oral anticoagulants (DOACs; e.g. rivaroxaban, edoxaban, apixaban) and low molecular weight heparin (LMWH; e.g. dalteparin, enoxaparin, tinzaparin) as standard of care for","cbCailpYWh4LES0O","https://ap.wps.com/l/cbCailpYWh4LES0O","pdf",1282640,11,"English","# Abstract\n## Background\n## Objectives\n## Methods\n## Results\n## Conclusions\n# Highlights\n# Keywords\n# Introduction\n# Methods\n## Ethical approval\n## Study design","[{\"question\":\"What clinical outcomes were compared between rivaroxaban and LMWH in cancer-associated CAT?\",\"answer\":\"The study compared incidence of recurrent VTE (rVTE), major bleeding, and all-cause mortality for patients with CAT treated with rivaroxaban versus LMWH.\"},{\"question\":\"How were patients with cancer-associated venous thromboembolism identified and followed?\",\"answer\":\"Patients with CAT were identified as venous thromboembolism occurring within 6 months of cancer diagnosis, using Swedish national registers from 2013–2019, then followed from the index CAT date to outcome, death, emigration, or end of study.\"},{\"question\":\"What were the main findings for recurrent VTE, major bleeding, and mortality?\",\"answer\":\"Rivaroxaban showed similar performance to LMWH for rVTE and major bleeding, while an all-cause mortality benefit was observed for rivaroxaban, potentially related to residual confounding.\"}]","Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism - a Swedish national population-based register study | PDF",1790049917,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/313d1d3e5b83977126b4570e294d960e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad9d7f7216e6bed07f3ea38faf9fd130.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00d274646e4d550ac24d802956f6f622.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9169ea4620f6999a42f17b34e84b0095.webp",980,1301]